FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252143136> ?p ?o ?g. }

• W4252143136 endingPage "8272" @default.
• W4252143136 startingPage "8272" @default.
• W4252143136 abstract "8272 Background: The growth factor filgrastim (G-CSF) reduces the severity and duration of neutropenia in cancer patients. Due to its short half-life, it has to be injected daily, usually for 7–10 days, which is a special challenge in treating children. Pegfilgrastim, a pegylated form of G-CSF, has a long half-life and thus only has to be injected once per chemotherapy cycle. Data on the use of pegfilgrastim in children is limited. Therefore we evaluated the safety and efficacy of pegfilgrastim in children. Methods: To date, we have retrospectively reviewed the charts of 21 pediatric patients (12 males, ages 4–20, median 13 yrs) with various cancers (19 solid tumors and 2 lymphomas) who received pegfilgrastim. All patients had life expectancy > 6 weeks and baseline lab values acceptable to receive chemotherapy. A total of 101 doses (median/patient 5, range 2–9) of pegfilgrastim were administered (98% 24–72 hours post-chemotherapy). Patients ≥ 45 kg received 6 mg each (44 doses), and patients < 45 kg received an average dose of 110 mcg/kg (57 doses). We evaluated the efficacy [measured by total white blood cell (WBC) recovery] and safety [measured by adverse drug reactions (ADRs)] of pegfilgrastim in these patients. Results: Of the 101 pegfilgrastim doses, 82 were followed by grade 3 or 4 neutropenia [absolute neutrophil count (ANC) < 1 x 109/L], 13 were not, and six could not be evaluated because of infrequent clinic visits. For the doses involving neutropenia, the average time to achieving an ANC ≥ 1 x 109/L was 10 days. For the 95 evaluable doses, the average time to peak WBC count was 12.5 days, and 25 admissions for febrile neutropenia (grade 3 or 4) occurred prior to WBC recovery. Identifiable ADRs included: 4 episodes of bone/muscular pain, 1 episode of chills, and 28 episodes of leukocytosis (8 cases of WBC > 2 times upper limit of normal for age). No reports of organ dysfunction were noted. Conclusions: Pegfilgrastim appears to be a safe and effective alternative to G-CSF in children with cancer, and we continue to use this agent at our center. No significant financial relationships to disclose." @default.
• W4252143136 created "2022-05-12" @default.
• W4252143136 creator A5003536492 @default.
• W4252143136 creator A5007711247 @default.
• W4252143136 creator A5018384953 @default.
• W4252143136 creator A5043483361 @default.
• W4252143136 creator A5045006924 @default.
• W4252143136 creator A5047568652 @default.
• W4252143136 creator A5079861456 @default.
• W4252143136 date "2004-07-15" @default.
• W4252143136 modified "2023-09-27" @default.
• W4252143136 title "Safety and efficacy of pegfilgrastim in pediatric oncology patients: The M.D. Anderson Cancer Center experience" @default.
• W4252143136 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.8272" @default.
• W4252143136 hasPublicationYear "2004" @default.
• W4252143136 type Work @default.
• W4252143136 citedByCount "0" @default.
• W4252143136 crossrefType "journal-article" @default.
• W4252143136 hasAuthorship W4252143136A5003536492 @default.
• W4252143136 hasAuthorship W4252143136A5007711247 @default.
• W4252143136 hasAuthorship W4252143136A5018384953 @default.
• W4252143136 hasAuthorship W4252143136A5043483361 @default.
• W4252143136 hasAuthorship W4252143136A5045006924 @default.
• W4252143136 hasAuthorship W4252143136A5047568652 @default.
• W4252143136 hasAuthorship W4252143136A5079861456 @default.
• W4252143136 hasConcept C126322002 @default.
• W4252143136 hasConcept C141071460 @default.
• W4252143136 hasConcept C197934379 @default.
• W4252143136 hasConcept C2776694085 @default.
• W4252143136 hasConcept C2777063308 @default.
• W4252143136 hasConcept C2777767877 @default.
• W4252143136 hasConcept C2778658803 @default.
• W4252143136 hasConcept C2778850193 @default.
• W4252143136 hasConcept C2779171977 @default.
• W4252143136 hasConcept C71924100 @default.
• W4252143136 hasConcept C74133956 @default.
• W4252143136 hasConceptScore W4252143136C126322002 @default.
• W4252143136 hasConceptScore W4252143136C141071460 @default.
• W4252143136 hasConceptScore W4252143136C197934379 @default.
• W4252143136 hasConceptScore W4252143136C2776694085 @default.
• W4252143136 hasConceptScore W4252143136C2777063308 @default.
• W4252143136 hasConceptScore W4252143136C2777767877 @default.
• W4252143136 hasConceptScore W4252143136C2778658803 @default.
• W4252143136 hasConceptScore W4252143136C2778850193 @default.
• W4252143136 hasConceptScore W4252143136C2779171977 @default.
• W4252143136 hasConceptScore W4252143136C71924100 @default.
• W4252143136 hasConceptScore W4252143136C74133956 @default.
• W4252143136 hasIssue "14_suppl" @default.
• W4252143136 hasLocation W42521431361 @default.
• W4252143136 hasOpenAccess W4252143136 @default.
• W4252143136 hasPrimaryLocation W42521431361 @default.
• W4252143136 hasRelatedWork W1589244631 @default.
• W4252143136 hasRelatedWork W2012078896 @default.
• W4252143136 hasRelatedWork W2015839741 @default.
• W4252143136 hasRelatedWork W2053128632 @default.
• W4252143136 hasRelatedWork W2098836775 @default.
• W4252143136 hasRelatedWork W2099191657 @default.
• W4252143136 hasRelatedWork W2158561707 @default.
• W4252143136 hasRelatedWork W2164788594 @default.
• W4252143136 hasRelatedWork W3141831760 @default.
• W4252143136 hasRelatedWork W4298277835 @default.
• W4252143136 hasVolume "22" @default.
• W4252143136 isParatext "false" @default.
• W4252143136 isRetracted "false" @default.
• W4252143136 workType "article" @default.